Methods for Using Aggregate Historical Control Data in Meta-Analyses of Clinical Trials With Time-to-Event Endpoints

被引:4
|
作者
Holzhauer, Bjorn [1 ]
机构
[1] Novartis Pharma AG, Biostat Sci & Pharmacometr, Basel, Switzerland
来源
关键词
Bayesian model averaging; Rare events; Robust meta-analytic predictive prior; Safety meta-analysis; Shrinkage priors; ANALYTIC-PREDICTIVE PRIORS; INFORMATION;
D O I
10.1080/19466315.2019.1610043
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
This article deals with comparing a test with a control therapy using meta-analyses of data from randomized controlled trials with a time-to-event endpoint. Such analyses can often benefit from prior information about the distribution of control group outcomes. One possible source of this information is the published aggregate data about control groups of historical trials from the medical literature. We review methods for making posterior inference about exponentially distributed event times more robust to prior-data conflicts by discounting the prior information based on the extent of observed prior-data conflict. We use simulations to compare analyses without prior information with the meta-analytic combined, meta-analytic predictive and robust meta-analytic predictive approaches, as well as Bayesian model averaging using shrinkage priors. Bayesian model averaging via shrinkage priors with well-chosen hyperpriors performed best in terms of credible interval coverage and mean-squared error across scenarios. For the robust meta-analytic predictive approach, there was little benefit in increasing the weight of the informative mixture components beyond 0.2-0.5. This was the case even when little prior-data conflict was expected, except with very sparse data or substantial between-trial heterogeneity in control group hazard rates. for this article are available online.
引用
收藏
页码:107 / 116
页数:10
相关论文
共 50 条
  • [1] Meta-analysis of clinical trials with competing time-to-event endpoints
    Meddis, Alessandra
    Latouche, Aurelien
    Zhou, Bingqing
    Michiels, Stefan
    Fine, Jason
    [J]. BIOMETRICAL JOURNAL, 2020, 62 (03) : 712 - 723
  • [2] LEVERAGING REAL-WORLD DATA FOR TIME-TO-EVENT ENDPOINTS IN CLINICAL TRIALS
    Parashar, D.
    Almgren, P.
    Berglund, A.
    Guasconi, A.
    Smith, C.
    Torlinska, B.
    Wang, J.
    Wang, Q.
    [J]. VALUE IN HEALTH, 2022, 25 (01) : S256 - S256
  • [3] The use of historical priors to improve the efficiency of phase II clinical trials with time-to-event endpoints
    Richard Jackson
    Trevor Cox
    Catrin Tudur-Smith
    [J]. Trials, 14 (Suppl 1)
  • [4] Effects of adjusting for censoring on meta-analyses of time-to-event outcomes
    Vale, CL
    Tierney, JF
    Stewart, LA
    [J]. INTERNATIONAL JOURNAL OF EPIDEMIOLOGY, 2002, 31 (01) : 107 - 111
  • [5] Comparison of Time-to-Event Data for Clinical Trials
    Nadarajah, Saralees
    [J]. MONTE CARLO METHODS AND APPLICATIONS, 2007, 13 (01): : 21 - 35
  • [6] Heterogeneous treatment effects in stratified clinical trials with time-to-event endpoints
    Beisel, Christina
    Benner, Axel
    Kunz, Christina
    Kopp-Schneider, Annette
    [J]. BIOMETRICAL JOURNAL, 2017, 59 (03) : 511 - 530
  • [7] A multistate platform model for time-to-event endpoints in oncology clinical trials
    Lin, Chih-Wei
    Nagase, Mario
    Doshi, Sameer
    Dutta, Sandeep
    [J]. CPT-PHARMACOMETRICS & SYSTEMS PHARMACOLOGY, 2024, 13 (01): : 154 - 167
  • [8] Sample sizes for clinical trials with time-to-event endpoints and competing risks
    Schulgen, G
    Olschewski, M
    Krane, V
    Wanner, C
    Ruf, G
    Schumacher, M
    [J]. CONTEMPORARY CLINICAL TRIALS, 2005, 26 (03) : 386 - 396
  • [9] Aggregate data meta-analysis with time-to-event outcomes
    Williamson, PR
    Smith, CT
    Hutton, JL
    Marson, AG
    [J]. STATISTICS IN MEDICINE, 2002, 21 (22) : 3337 - 3351
  • [10] Power considerations for clinical trials using multivariate time-to-event data
    Hughes, MD
    [J]. STATISTICS IN MEDICINE, 1997, 16 (08) : 865 - 882